Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
74 75 Next >
News headline image
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
Via Benzinga
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
News headline image
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
Is NASDAQ:AZN a Suitable Choice for Quality Investing? ↗
Why Quality-Oriented Investors Should Consider NASDAQ:AZN. 
Via Chartmill
News headline image
3 Market-Beating Stocks to Buy for Less Than $100 ↗
These stocks are all up more than 20% this year. 
Via The Motley Fool
News headline image
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities ↗
Chinese police detain AstraZeneca employees over alleged data privacy breaches and unlicensed drug imports amid an anti-corruption drive. 
Via Benzinga
Topics Law Enforcement
News headline image
Reasonable Growth, Debt Levels, and a High ROIC Make ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Appealing to Quality Investors. ↗
Why ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Deserves Consideration as a Quality Investment. 
Via Chartmill
News headline image
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity ↗
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is... 
Via Benzinga
News headline image
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
News headline image
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
From AstraZeneca
Via Business Wire
News headline image
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
News headline image
Biotech And Life Science Sector Update Summer Of 2024 ↗
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
News headline image
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support ↗
AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life... 
Via Benzinga
News headline image
Biotech Bull Market: 3 Ways To Play It ↗
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
News headline image
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested ↗
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization... 
Via Benzinga
News headline image
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave ↗
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer ↗
FDA approves AstraZeneca's Imfinzi with chemotherapy for early-stage lung cancer, based on pivotal AEGEAN trial. Imfinzi shows significant event-free survival and pathologic complete response benefits.... 
Via Benzinga
News headline image
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
From AstraZeneca
Via Business Wire
News headline image
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations ↗
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
News headline image
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding ↗
AstraZeneca is raising concerns that a manufacturing site could be relocated to France, putting an investment in jeopardy. 
Via Benzinga
News headline image
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
AstraZeneca, T-Mobile US, and Intuitive Surgical are hitting all-time highs, driven by solid sector performance, robust earnings, and strategic advancements. 
Via MarketBeat
Topics ETFs
News headline image
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct ↗
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth. 
Via InvestorPlace
News headline image
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows ↗
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
Via Benzinga
News headline image
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules ↗
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical... 
Via Benzinga
News headline image
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows ↗
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
News headline image
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets ↗
Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.